Taken together, our findings suggest that USP2 stabilizes Mdm2 which antagonizes pro-apoptotic activity of p53 and possibly contributes to therapeutic resistance in CTCL. This evidence concerns the gene TP53 and primary cutaneous T-cell non-Hodgkin lymphoma.